Editas Medicine, Inc. (EDIT) Stock Profile — Insider Trades & Financials

Revenue$11.9M

Net Income-$18.2M

EPS$-0.40

Market Cap$239.3M

Price Performance

Historical data including institutional events

Company Profile

Gilmore O’Neill

CEO & Executive Director

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Founded: 2013
Employees: 226
Headquarters: CAMBRIDGE, MA, United States
Website: www.editasmedicine.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Revenue$11.9M

Net Income-$18.2M

EPS$-0.40

Market Cap$239.3M

Price Performance

Historical data including institutional events

Company Profile

Gilmore O’Neill

CEO & Executive Director

Founded: 2013
Employees: 226
Headquarters: CAMBRIDGE, MA, United States
Website: www.editasmedicine.com

Peer ComparisonRevenue ($B)

▾

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER GRANT / AWARDLinda Burkly (EVP, CHIEF SCIENTIFIC OFFICER) GRANT / AWARD EDITMar 12, 2026

INSIDER SELLLinda Burkly (EVP, CHIEF SCIENTIFIC OFFICER) SELL EDITJun 3, 2026

INSIDER SELLGilmore Neil O'Neill (CEO) SELL EDITJun 3, 2026

INSIDER SELLAmy Parison (SVP, Chief Financial Officer) SELL EDITJun 3, 2026

INSIDER GRANT / AWARDElliott M. Levy (Director) GRANT / AWARD EDITJun 17, 2026

INSIDER GRANT / AWARDDavid Scadden (Director) GRANT / AWARD EDITJun 17, 2026

INSIDER GRANT / AWARDAndrew Hirsch (Director) GRANT / AWARD EDITJun 17, 2026

INSIDER GRANT / AWARDJessica Hopfield (Director) GRANT / AWARD EDITJun 17, 2026

INSIDER GRANT / AWARDBernadette Connaughton (Director) GRANT / AWARD EDITJun 17, 2026

INSIDER SELLLinda Burkly (EVP, CHIEF SCIENTIFIC OFFICER) SELL EDITJul 28, 2026

INSIDER SELLAmy Parison (SVP, Chief Financial Officer) SELL EDITAug 3, 2026

INSIDER GRANT / AWARDPatrick Thomas Ellinor II (Director) GRANT / AWARD EDITAug 6, 2026

INSIDER SELLGilmore Neil O'Neill (CEO) SELL EDITSep 3, 2026

INSIDER SELLLinda Burkly (EVP, CHIEF SCIENTIFIC OFFICER) SELL EDITSep 3, 2026

INSIDER SELLAmy Parison (SVP, Chief Financial Officer) SELL EDITSep 3, 2026

INSIDER GRANT / AWARDDaniel Scott Ory (EVP, Chief Medical Officer) GRANT / AWARD EDITSep 8, 2026

⚡

Core Efficiency

ROE?

-17.32%

ROA?

-7.68%

D/E Ratio?

1.25

Op. Margin?

-156.05%

📊

Profitability Ratios

Net Margin?

-153.32%

Current Ratio?

3.19

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 15, 2026 (in 32 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 15, 2026

Predicted10-Q

Aug 5, 2026

10-QQ2 202636d after period end

May 5, 2026

10-QQ1 202635d after period end

Mar 9, 2026

10-KQ4 202568d after period end

Mar 9, 2026

10-KFY 202568d after period end

Nov 10, 2025

10-QQ3 202541d after period end

Aug 12, 2025

10-QQ2 202543d after period end

May 12, 2025

10-QQ1 202542d after period end

Mar 5, 2025

10-KQ4 202464d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-05

SEC Metadata

2mo ago

Latest filing: 2026-08-05

Loading company sections...

Editas Medicine, Inc.

Price Performance

Company Profile

Editas Medicine, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

Editas Medicine, Inc.

Price Performance

Company Profile

The morning brief, before the bell.

Editas Medicine, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades